Semaglutide slows the progression of cognitive impairment and pathological changes in the hippocampus in a model of Alzheimer's disease
Currently, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are considered promising drugs for the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases due to their complex mechanism of action, which includes (in addition to general somatic effects) an impact on neuroplasti...
שמור ב:
| Principais autores: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Russo |
| יצא לאור: |
IMA-PRESS LLC
2025-12-01
|
| סדרה: | Неврология, нейропсихиатрия, психосоматика |
| נושאים: | |
| גישה מקוונת: | https://nnp.ima-press.net/nnp/article/view/2738 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|